Top Markets
#1 GEKKO GEKKO +53.94%
#2 Helium Helium +47.23%
#3 Pons Pons +25.55%
#4 Main Street Yield Main Street Yield +17.48%
#5 龙虾 (Lobster) 龙虾 (Lobster) +15.91%
#6 Collect on Fanable Collect on Fanable +14.24%
#7 o1.exchange o1.exchange +14.04%
#8 Ontology Gas Ontology Gas +11.63%
#9 Nockchain Nockchain +11.47%
#10 OpenGradient OpenGradient +10.61%
Coin of the day
GEKKO GEKKO
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Corvus Pharmaceuticals, Inc. Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc.

CRVS
Classement en actions #8729
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
Prix de l'action
$14.07
Dernière synchronisation: 2026-08-28
Capitalisation boursière
$1.18B
Changement (1 jour)
-4.41%
Changement (1 an)
145.13%
Pays
US
Échange Corvus Pharmaceuticals, Inc. (CRVS)

Catégorie

Healthcare
Historique du prix de l'action pour Corvus Pharmaceuticals, Inc. (CRVS)
Prix de clôture le plus élevé : $14.55 le 2026-08-01

Prix de clôture le plus bas : $14.35 le 2016-03-01
Historique du prix de l'action de Corvus Pharmaceuticals, Inc. de 2016 à 2026
Performance annuelle du prix de l'action
Année Performance
2026 (TTM) 52.04%
2025 20.69%
2024 304.94%
2023 86.02%
2022 -68.55%
2021 -28.60%
2020 -6.17%
2019 -13.67%
2018 -53.58%
2017 -32.68%
2016 0.00%
Prix de l'action pour des entreprises similaires ou concurrentes
Entreprise Prix de l'action Variation 1a% Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $542.09 38.63%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.03K 44.13%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $121.53 -12.70%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $138.18 473.58%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $759.27 7.20%
CH